Simon Estcourt
Simon joins TMC from Abacus Medicine Pharma Services, where he was Managing Director, successfully growing the company by partnering with developers of innovative therapies and tailoring bespoke commercialisation solutions. After graduating with a degree in Business and Politics from Aston University, Simon began his career in the pharmaceutical services industry working in business development for Quintiles/Innovex for a number of years before joining Idis, gaining extensive global experience in corporate development, strategic planning, executive management and leadership at director and senior vice president roles, graduating to president status leading the managed access programs division. After joining the Clinigen Group, he continued working at C-suite level, prior to his last role at Abacus before joining TMC.
Simon brings a wealth of senior leadership experience in the pharma services space and will support TMC with its continued global expansion.
Simon joined TMC in May 2024.
Carol Woodward
Carol has extensive experience across many therapeutic areas, particularly oncology and all development phases. She has held roles in both Pharma companies and Clinical Research Organisations, including senior positions such as the Global Therapeutic Head of Haematology/Oncology at PPD and Vice President Development Innovations and European Operations at Sarah Cannon.
Carol joined TMC in March 2020.
Stewart Sharpe
Stewart has a wealth of expertise gained across a variety of specialty, rare/orphan and specialist diseases: hepatology, metabolic diseases, CV, GI, HIV, oncology, transplantation and respiratory. Previously, he held senior global roles with Syneos Health, Intercept, Circassia, OSI Pharmaceuticals, Johnson & Johnson, Novartis, Roche and GSK. He also served as Deputy Chair and non-executive director on the board of the UK’s Oxford Biosciences Network (OBN).
Stewart joined TMC in June 2023
Joe Lopez
Joe joins TMC from Sondrel Holdings plc, where he was Chief Financial Officer and successfully took the company public in 2022. He has been a chartered accountant for over 25 years and Chief Financial Officer for 15 years, primarily focused on international businesses.
Qualifying originally with Grant Thornton, he has worked in a variety of directorship roles in the UK and Europe, ranging from start-ups to corporate multi nationals, bringing with him extensive executive management and growth management experience of delivering sustainable value in international environments that will ably support TMC’s continued global expansion.
Joe joined TMC in May 2024.
Catherine Moncad
Catherine has held regulatory roles at Smith & Nephew and PRA, gaining extensive experience in OTCs, generics, devices, prescription pharmaceuticals and wide clinical trial experience.
Since joining TMC, she heads the Regulatory Services team that supports clients with all stages of drug development from early non-clinical, through to clinical, to licence applications and even post-approval support.
Catherine joined TMC in March 2017.
Marcelo Vaz
Marcelo developed clinical research expertise across the range of respiratory diseases, including COPD, Asthma, Lung Cancer, Cystic Fibrosis, Respiratory infections, Sepsis, mechanical ventilation, ARDS and SIRS.
Other areas of clinical research experience include CV, TGI, rheumatology, woman’s health, oncology, ENT, CNS, DM. His rare diseases expertise includes supporting strategic creation of drug development plans, protocol concepts, and moving from classic to adaptive study designs.
Marcelo joined TMC in 2022.
Lucy Fulford-Smith
Since becoming a Pharmaceutical Physician in 2020, Lucy has worked in early clinical development, pharmacovigilance and medical information. She has experience working at multiple stages of the development of gene and cell therapies and has particular interest in treatments for rare diseases, oncology and paediatric indications.
As Head of PV, Lucy leads a growing team of pharmacovigilance specialists delivering clinical trial and post-marketing PV expertise. In her role as Medical Director, Lucy supports all aspects of the medical services scope of work, including clinical trials, licensing applications and post-marketings activities.
Lucy joined TMC in 2022.
Dr Victoria Datsenko
A medically qualified doctor, her extensive experience covers all clinical trial phases across a broad range of indications and therapies with particular expertise in oncology and cell therapy.
Victoria’s Clinical Services team comprises experienced and highly capable Project Directors, Project Managers, CRAs and CTAs allowing her direct oversight and governance of all aspects of our clinical projects.
Victoria joined TMC in 2022.